The $16.6 billion acquisition will bring Abiomed’s breakthough Impella heart pumps into the Johnson & Johnson MedTech portfolio.
Physicians are looking for better ways to treat patients with congestive heart failure. This includes the integration of remote monitoring and novel technologies.
Although the medtech industry is expected to enjoy steady growth, device companies are still challenged to attract the skilled labor that manufacturing requires.
The certification comes at a time when many companies have been saying that the May 2020 deadline is too soon.
This major health threat is driving demand for more diagnostic tests and devices to treat cardiac problems.
Despite pricing pressures, several sectors within the medical device industry can expect to enjoy growth and attract attention from investors.
The Children’s National Health System is accepting proposals for technologies that address unmet needs in children.
The company continues to drive global expansion by investing in high growth segments and expanding its innovation pipeline to new markets.
As CVD rates rise, so does the demand for devices that improve heart function and blood flow.
The union of the two companies creates a market opportunity of nearly $30 billion.